Oral vs Injectable vs Nasal vs Topical Delivery
Each delivery route trades off bioavailability, onset, convenience, and which molecules are practical to deliver. Injectables generally offer the most reliable systemic exposure for peptides. Oral troches and lozenges bypass first-pass metabolism for selected molecules. Nasal sprays act on accessible mucosa, and topical preparations act locally. Route selection is a clinical decision.
What's being compared
Tablets, capsules, troches, or lozenges; bioavailability depends on the molecule.
Subcutaneous or intramuscular injection; the standard route for many peptides.
Intranasal preparations acting on accessible mucosa or for selected systemic delivery.
Creams, gels, or patches; primarily local action in most preparations.
Side-by-side comparison
| Attribute | Oral | Injectable | Nasal | Topical |
|---|---|---|---|---|
| Typical absorption profile | Variable; peptides are typically degraded by gastric acid and proteases unless specifically formulated. | Predictable systemic exposure; the reference route for many peptide and hormone protocols. | Direct absorption across nasal mucosa for selected small peptides. | Primarily local action; systemic absorption is generally low. |
| Onset and duration | Onset minutes to an hour depending on formulation; sublingual or buccal absorption can be faster than swallowed tablets. | Onset minutes for subcutaneous or intramuscular routes; weekly depots are also common. | Onset typically minutes for intranasal preparations. | Local action begins on application; systemic onset (when relevant) is typically slower. |
| Molecules typically used | NAD+ troches, methylene blue capsules, oxytocin troches in compounded form. | GLP-1s, GHRH analogs, GH secretagogues, BPC-157, TB-500, testosterone esters. | Selected smaller peptides such as some neuropeptide and reproductive-axis molecules. | Hair restoration blends, skin-restorative blends, GHK-Cu preparations. |
| Patient convenience | Highest day-to-day convenience for patients comfortable with self-dosing. | Requires comfort with self-injection; weekly dosing reduces frequency for some molecules. | Convenient for small-volume single-actuation dosing. | Convenient for applied-area protocols. |
| Supplies required | No syringes; refrigeration depending on formulation. | Syringes, needles, sharps disposal; refrigeration depending on molecule. | Single-use or multi-use sprayer; refrigeration depending on formulation. | Tube or pump applicator; storage per formulation. |
| Patient training | Minimal; simple patient instruction. | Patient training on injection technique, site rotation, and sharps handling. | Patient training on actuation and head positioning. | Patient training on application area and frequency. |
| Regulatory status by route | Both FDA-approved finished products (e.g. tablets, capsules) and 503A/503B compounded troches and capsules exist; compounded forms are not FDA-approved. | Many FDA-approved injectable products exist; clinician-directed compounded injectables are dispensed by 503A/503B pharmacies and are not FDA-approved. | FDA-approved nasal sprays exist for some indications; compounded nasal preparations are 503A/503B and are not FDA-approved. | FDA-approved topical drug products exist; compounded topical preparations are 503A/503B and are not FDA-approved. |
| Evidence base | Strong general pharmacology literature on oral absorption; peptide-specific oral evidence is limited to molecules with favorable formulation. | Largest published trial literature for peptide and hormone protocols; the reference route for most regulated studies. | Published evidence concentrated on smaller peptides and on local nasal-mucosa indications. | Published evidence concentrated on local-action use cases for skin, scalp, or wound contexts. |
| Typical clinician use case | Considered when patient preference favors a non-injectable route and the molecule has a workable oral or sublingual formulation. | Considered when reliable systemic exposure is the goal and the molecule is not orally bioavailable. | Considered for select smaller peptides or when nasal-mucosa action is the clinical target. | Considered when the goal is local action on skin or scalp rather than systemic exposure. |
| Example Regen Therapy categories | Methylene Blue Capsules. | RT-01, RT-02, RT-04, RT-05, RT-CS-05 protocols in the Regen Therapy catalog. | Selected nasal preparations available through compounding partners on clinician request. | Skin-restorative protocols available through compounding partners. |
Which one might fit?
Use the framings below as orientation only. The right therapy is determined by your prescribing clinician based on history, lab work, and the specifics of your situation.
Injectable routes are the reference choice for most peptides because oral bioavailability is limited for many of them.
A topical preparation is typically the right starting point — systemic exposure is generally not the goal.
Oral troches, lozenges, or nasal preparations are the categories where clinician-directed alternatives most often exist for the molecule in question.
Talk to a clinician about which fits
Every Regen Therapy protocol is reviewed by a licensed clinician and dispensed by Wells Pharmacy Network only after evaluation. Start with a brief intake to see what makes sense for your situation.
Frequently asked questions
Why are most peptides injected?
Most peptides are degraded by the digestive tract, so oral bioavailability is limited. Subcutaneous or intramuscular injection delivers the molecule into circulation in a predictable way for many peptide protocols.
Are oral peptides effective?
Some molecules are formulated for oral or troche delivery successfully. Whether an oral preparation makes sense depends on the specific molecule, the formulation, and the clinical context — it is not a one-size-fits-all answer.
Are nasal sprays a substitute for injections?
Nasal delivery works well for some smaller peptides and for therapies acting on the nasal mucosa, but it is not a universal substitute for injection. The right route depends on the molecule.
Are topical peptides absorbed systemically?
Most topical peptide preparations are formulated for local action on skin or scalp. Systemic absorption is generally low and not the intended outcome.
How is the route chosen?
The prescribing clinician selects the route based on the molecule, the clinical question, the patient's history and preferences, and what formulations are available through the compounding pharmacy.
Are all of these routes available at Regen Therapy?
The Regen Therapy catalog includes injectable, oral troche/capsule, and topical protocols across categories. Specific availability is shown on each catalog page and is dispensed only after a clinician evaluation.